Airway Responses to Montelukast and Desloratadine. - Full Text View

Purpose

Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.

Condition	Intervention
Asthma	Drug: Montelukast (10mg) and Desloratadine (5mg)

MedlinePlus related topics:

Asthma

ChemIDplus related topics:

Montelukast Montelukast sodium

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study

Official Title:	Airway Responses to Montelukast and Desloratadine.

Further study details as provided by University of Saskatchewan:

Primary Outcome Measures:

Late asthmatic response (maximum percent decrease in FEV1)

Secondary Outcome Measures:

Early asthmatic response (maximum percent decrease in FEV1
Changes in sputum cell/mediator content
Changes in airway hyperresponsiveness (methacholine PC20)

Estimated Enrollment:	12
Study Start Date:	January 2007
Study Completion Date:	August 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

baseline FEV1 > or = 65% predicted
positive methacholine challenge (i.e. methacholine PC20 < or = 16mg/ml
positive allergen challenge

Exclusion Criteria:

negative skin prick test
lung condition/disease other than asthma
currently use montelukast and/or desloratadine

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00424580

Locations


Canada, Saskatchewan
	Room 346 Ellis Hall
	Saskatoon, Saskatchewan, Canada, S7N 0W8

Sponsors and Collaborators

University of Saskatchewan

Investigators


Principal Investigator:	Donald W Cockcroft, MD, FRCP(C)	University of Saskatchew Full Professor

More Information

Responsible Party:	Department of Medicine, University of Saskatchewan ( Dr. Donald W. Cockcroft )
Study ID Numbers:	BIO-REB# 06-232
First Received:	January 18, 2007
Last Updated:	January 18, 2008
ClinicalTrials.gov Identifier:	NCT00424580
Health Authority:	Canada: Health Canada

Study placed in the following topic categories:

Montelukast

Histamine phosphate

Asthma

Desloratadine

Histamine

Leukotriene Antagonists

Additional relevant MeSH terms:

Respiratory System Agents

Neurotransmitter Agents

Cholinergic Antagonists

Molecular Mechanisms of Pharmacological Action

Hormone Antagonists

Physiological Effects of Drugs

Hormones, Hormone Substitutes, and Hormone Antagonists

Histamine Agents

Anti-Asthmatic Agents

Cholinergic Agents

Pharmacologic Actions

Histamine Antagonists

Therapeutic Uses

Histamine H1 Antagonists

Histamine H1 Antagonists, Non-Sedating

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	University of Saskatchewan
Information provided by:	University of Saskatchewan
ClinicalTrials.gov Identifier:	NCT00424580